Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BNR
BNR logo

BNR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Burning Rock Biotech Ltd (BNR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
16.760
1 Day change
1.09%
52 Week Range
41.720
Analysis Updated At
2026/05/08
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

BNR is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is weak technically, there is no supportive options or trading signal, no recent news catalyst, and the latest quarter shows only minimal revenue growth with sharply worse profitability. If you want immediate action and do not want to wait for a better entry, this is still not an attractive long-term buy today.

Technical Analysis

BNR is in a weak short-term trend. The price closed at 16.46, below the pivot level of 17.97 and only modestly above S1 at 15.83, which suggests it is trading near support but not showing strength. MACD histogram is negative and expanding, indicating bearish momentum. RSI_6 at 29.84 is near oversold territory, but not a strong reversal confirmation. Moving averages are converging, which points to a consolidation phase rather than a confirmed uptrend. Overall, technicals do not support an immediate buy.

Positive Catalysts

  • Gross margin improved significantly to 78.03% in 2025/Q4, up 9.96% YoY, which is a constructive operational sign. Similar candlestick pattern analysis suggests a 70% chance of a 3.47% gain next day, 0.95% over the next week, and 7.62% over the next month. The stock is also hovering near support, which could help if a rebound develops.

Neutral/Negative Catalysts

  • No news in the recent week means there is no event-driven catalyst. Revenue growth in 2025/Q4 was essentially flat at 0.23% YoY, while net income fell to -15.39M and EPS dropped to -0.15, both down about 81% YoY. Hedge funds and insiders are neutral with no significant trading trends. AI Stock Picker shows no signal today, and SwingMax shows no recent signal. Congress trading data is unavailable, so there is no supportive political buying signal.

Financial Performance

In 2025/Q4, BNR delivered flat revenue growth, with revenue up only 0.23% YoY to 126.315M. Gross margin improved materially to 78.03%, but profitability weakened sharply, with net income declining 81.07% YoY to -15.386M and EPS falling 81.01% YoY to -0.15. The latest quarter suggests better operating efficiency, but the company is still losing money and not showing strong growth momentum.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no evidence of recent Wall Street upgrades or target increases. Based on the available data, Wall Street sentiment appears neutral at best: no clear pros-side catalyst from analysts, and the cons-side view is supported by weak earnings, flat revenue growth, and the absence of positive recent news.

Wall Street analysts forecast BNR stock price to rise
Analyst Rating
0
Wall Street analysts forecast BNR stock price to rise
Buy
Hold
Sell
0
Current: 16.760
sliders
Low
0
Averages
0
High
0
0
Current: 16.760
sliders
Low
0
Averages
0
High
0
Morgan Stanley
Annelies Vermeulen
Equal Weight -> Underweight
downgrade
AI Analysis
2026-01-06
Reason
Morgan Stanley
Annelies Vermeulen
Price Target
AI Analysis
2026-01-06
downgrade
Equal Weight -> Underweight
Reason
Morgan Stanley analyst Annelies Vermeulen downgraded Brenntag to Underweight from Equal Weight with a price target of EUR 50, down from EUR 63. The firm adjusted rating in the European business services group as part of its 2026 outlook. The analyst is cautious on the staffers and chemical distribution. Morgan Stanley's preferred stocks for 2026 are Experian, Diploma, Rentokil, Verisure, Bureau Veritas and ISS.
Berenberg
Hold
downgrade
2025-12-10
Reason
Berenberg
Price Target
2025-12-10
downgrade
Hold
Reason
Berenberg lowered the firm's price target on Brenntag to EUR 48 from EUR 51 and keeps a Hold rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BNR
Unlock Now

People Also Watch